does tirzepatide cause heart palpitations Zepbound Issues? Cardiovascular Safety Explained How Tirzepatide Supports Cardiovascular Health

Nausea incidence with GLP-1 therapies varies by agent, dose, and population, but current research indicates that roughly one in five to one in two users experience some nausea, most often during the first weeks of therapy

But robust human clinical evidence specifically for disc herniations is still developing

If you have one of these conditions, a supplement may be beneficial

15 In addition to the aforementioned 20% reduction in risk for the primary outcome, secondary endpoint analyses revealed nonsignificant relative risk reductions of 15%, 18%, 19%, and 73% for cardiovascular death, heart failure hospitalization, all-cause mortality, and progression to type 2 diabetes, respectively

& Mayerl, S